Repository logo
 
Publication

Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors

2021Journal article Open access
Simple item page
dc.contributor.authorNappi, L
dc.contributor.authorThi, M
dc.contributor.authorAdra, N
dc.contributor.authorHamilton, RJ
dc.contributor.authorLeao, R
dc.contributor.authorLavoie, JM
dc.contributor.authorSoleimani, M
dc.contributor.authorEigl, BJ
dc.contributor.authorChi, K
dc.contributor.authorGleave, M
dc.contributor.authorSo, A
dc.contributor.authorBlack, PC
dc.contributor.authorBell, R
dc.contributor.authorDaneshmand, S
dc.contributor.authorCary, C
dc.contributor.authorMasterson, T
dc.contributor.authorEinhorn, L
dc.contributor.authorNichols, C
dc.contributor.authorKollmannsberger, C
dc.date.accessioned2023-02-05T16:58:44Z
dc.date.available2023-02-05T16:58:44Z
dc.date.issued2021
dc.description.abstractActive germ cell malignancies express high levels of specific circulating micro-RNAs (miRNAs), including miR-371a-3p (miR371), which is undetectable in teratoma. Teratoma markers are urgently needed for theselection of patients and treatments because of the risk of malignant transformation and growing teratoma syndrome. To assess the accuracy of plasma miR375 alone or in combination with miR371 in detecting teratoma, 100 germ cell tumor patients, divided into two cohorts, were enrolled in a prospective multi-institutional study. In the discovery cohort, patients with pure teratoma and with no/low risk of harboring teratoma were compared; the validation cohort included patients with confirmed teratoma, active germ cell malignancy, or complete response after chemotherapy. The area under the receiver operating characteristic curve values for miR375, miR371, and miR371-miR375 were, respectively, 0.93 (95% confidence interval [CI]: 0.87-0.99), 0.59 (95% CI: 0.44-0.73), and 0.95 (95% CI: 0.90-0.99) in the discovery cohort and 0.55 (95% CI: 0.36-0.74), 0.74 (95% CI: 0.58-0.91), and 0.77 (95% CI: 0.62-0.93) in the validation cohort. Our study demonstrated that the plasma miR371-miR375 integrated evaluation is highly accurate to detect teratoma. PATIENT SUMMARY: The evaluation of two micro-RNAs (miR375-miR371) in the blood of patients with germ cell tumors is promising to predict teratoma. This test could be particularly relevant to the identification of teratoma in patients with postchemotherapy residual disease.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEur Urol . 2021 Jan;79(1):16-19pt_PT
dc.identifier.doi10.1016/j.eururo.2020.10.024pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.26/43624
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectMicroRNAspt_PT
dc.subjectNeoplasias Embrionárias de Células Germinativaspt_PT
dc.subjectNeoplasias Testicularespt_PT
dc.subjectTeratomapt_PT
dc.subjectNeoplasms, Germ Cell and Embryonalpt_PT
dc.subjectTesticular Neoplasmspt_PT
dc.titleIntegrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumorspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage19pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage16pt_PT
oaire.citation.titleEuropean Urologypt_PT
oaire.citation.volume79pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors.pdf
Size:
550.57 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Saúde - CUF - Coimbra - Artigos Científicos